ContractWarrant Agreement • December 28th, 2017 • Vericel Corp • Biological products, (no disgnostic substances) • New York
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 8.3 AND 8.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
AMENDMENT NO. 5 TO LICENSE AGREEMENTLicense Agreement • December 28th, 2017 • Vericel Corp • Biological products, (no disgnostic substances) • New York
This Amendment No. 5 (“Amendment 5”) to the License Agreement (as defined below) dated as of December 5, 2017 (the “Amendment Date”), is entered into by and between “上海斯丹赛生物技术有限公司” (Innovative Cellular Therapeutics CO., LTD.), a corporation organized and existing under the laws of China (“ICT”), and Vericel Corporation, a corporation organized and existing under the laws of the State of Michigan (“Vericel”). Terms used, but not defined, herein shall have the meaning ascribed to them in the License Agreement.
AMENDMENT NO. 3 TO LETTER AGREEMENTLetter Agreement • December 28th, 2017 • Vericel Corp • Biological products, (no disgnostic substances) • New York
This Amendment No. 3 (“Amendment 3”) to the Letter Agreement (as defined below) dated as of October 9, 2017 (the “Amendment Date”), is entered into by and between “上海斯丹赛生物技术有限公司” (Innovative Cellular Therapeutics CO., LTD.), a corporation organized and existing under the laws of China (“ICT”), and Vericel Corporation, a corporation organized and existing under the laws of the State of Michigan (“Vericel”). Terms used, but not defined, herein shall have the meaning ascribed to them in the Letter Agreement. ICT and Vericel are each referred to herein as a “Party” or collectively the “Parties”.
AMENDMENT NO. 5 TO LETTER AGREEMENTLetter Agreement • December 28th, 2017 • Vericel Corp • Biological products, (no disgnostic substances) • New York
This Amendment No. 5 (“Amendment 5”) to the Letter Agreement (as defined below) dated as of December 5, 2017 (the “Amendment Date”), is entered into by and between “上海斯丹赛生物技术有限公司” (Innovative Cellular Therapeutics CO., LTD.), a corporation organized and existing under the laws of China (“ICT”), and Vericel Corporation, a corporation organized and existing under the laws of the State of Michigan (“Vericel”). Terms used, but not defined, herein shall have the meaning ascribed to them in the Letter Agreement. ICT and Vericel are each referred to herein as a “Party” or collectively the “Parties”.
AMENDMENT NO. 4 TO LICENSE AGREEMENTLicense Agreement • December 28th, 2017 • Vericel Corp • Biological products, (no disgnostic substances) • New York
This Amendment No. 4 (“Amendment “) to the License Agreement (as defined below) dated as of November 9, 2017 (the “Amendment Date”), is entered into by and between “上海斯丹赛生物技术有限公司” (Innovative Cellular Therapeutics CO., LTD.), a corporation organized and existing under the laws of China (“ICT”), and Vericel Corporation, a corporation organized and existing under the laws of the State of Michigan (“Vericel”). Terms used, but not defined, herein shall have the meaning ascribed to them in the License Agreement.
AMENDMENT NO. 4 TO LETTER AGREEMENTLetter Agreement • December 28th, 2017 • Vericel Corp • Biological products, (no disgnostic substances) • New York
This Amendment No. 4 (“Amendment 4”) to the Letter Agreement (as defined below) dated as of November 9, 2017 (the “Amendment Date”), is entered into by and between “上海斯丹赛生物技术有限公司” (Innovative Cellular Therapeutics CO., LTD.), a corporation organized and existing under the laws of China (“ICT”), and Vericel Corporation, a corporation organized and existing under the laws of the State of Michigan (“Vericel”). Terms used, but not defined, herein shall have the meaning ascribed to them in the Letter Agreement. ICT and Vericel are each referred to herein as a “Party” or collectively the “Parties”.
AMENDMENT NO. 3 TO LICENSE AGREEMENTLicense Agreement • December 28th, 2017 • Vericel Corp • Biological products, (no disgnostic substances) • New York
This Amendment No. 3 (“Amendment “) to the License Agreement (as defined below) dated as of October 9, 2017 (the “Amendment Date”), is entered into by and between “上海斯丹赛生物技术有限公司” (Innovative Cellular Therapeutics CO., LTD.), a corporation organized and existing under the laws of China (“ICT”), and Vericel Corporation, a corporation organized and existing under the laws of the State of Michigan (“Vericel”). Terms used, but not defined, herein shall have the meaning ascribed to them in the License Agreement.
